AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02291848 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAA-specific CTLs
Description: Groups A and B only: Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 5 x 10\^6 cells/m2 and Day 14: 5 x 10\^6 cells/m2~Dose Level Two:~Day 0: 1 x 10\^7 cells/m2 and Day 14: 1 x 10\^7 cells/m2~Dose Level Three:~Day 0 2 x 10\^7 cells/m2 and Day 14 2 x 10\^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion.
Study NCT02291848 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAA-specific CTLs- fixed dose
Description: Fixed dose of 2 x 10\^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion.
Study NCT04248335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: single-dose administration
Study NCT04248335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam injection
Description: single-dose administration
Study NCT04517838 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tumor tissue samples
Study NCT03541902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO
Study NCT03541902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study NCT01287884 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Venous Blood Gas
Description: patients who have been identified by the treating physician as needing an ABG will receive an VBG is they consent to take part in the study
Study NCT03592225 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational workshop
Description: the intervention is a 3 hours educational workshop designed to address all the potential questions that the general practitioners (GP) and their patients might have regarding HPV vaccination.
Study NCT03027414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation Sham
Description: TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
Study NCT03027414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
Study NCT03857503 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: iFR
Description: Patients will undergo standard of care diagnostic coronary angiography using established invasive physiological criteria for iFR and FFR to aid in clinical decision making for coronary revascularization.~Angiograms will be made in at least two projections, and the treating physician will record his/her estimation of stenosis severity.~Resting iFR and Pd/Pa measures will then be made distal to the target lesion; adenosine will be administered, and the FFR measures will be made without moving the wire. An iFR pullback will then be made after hyperemia as abated. Patients will be treated or deferred from treatment based on physician decision aided by the iFR measures.
Study NCT02166450 — intervention group
Intervention type: DRUG
Intervention: Nystatin
Description: 100 000 IU every 6 h as a suspension
Study NCT02339896 — intervention group
Intervention type: BIOLOGICAL
Intervention: rabies vaccine
Description: rabies vaccine 0.1 ml intradermal two site for 4 times
Study NCT03749447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl
Description: Bardoxolone methyl capsules
Study NCT03810534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect-Home
Description: Connect-Home will introduce organizational structure to support delivery of transitional care processes. New elements of structure include:electronic health record (EHR) template, Connect-Home Toolkit, and Staff Training. After structural elements are added, SNF staff will use Connect-Home care processes to deliver the 2-step transitional care intervention.In Step 1, SNF nurses, therapists, and social workers will develop a Transition Plan of Care and prepare the patient and caregiver to manage the patient's serious illness and functional needs. In Step 2, the Connect-Home Activation RN will visit the patient's home within 24 hours of discharge; the nurse will activate the Transition Plan of Care at home. Both intervention steps focus on 6 key care needs to optimize patient and caregiver outcomes: 1) home safety and level of assistance; 2) advance care planning; 3) symptom management; 4) medication reconciliation; 5) function and activity; and 6) coordination of follow-up medical care.
Study NCT03091647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acupressure intervention
Description: Women in the acupressure intervention group will learn how to press three chief energy acupoints on each side of the body through an 11-minute Chinese-language video and press three acupoints (1 minute per acupoint) on both sides of the body every day for a total of 6 minutes per day for an 8-week intervention period and record their practice on daily logs. Women will be asked to return the logs every week by email or self-addressed envelopes.
Study NCT03091647 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: Women in the usual care group will receive primary and oncology care from their doctors as usual, and complete daily logs recording their fatigue and daily functioning levels. They also need to return the logs every week by email or self-addressed envelopes.
Study NCT00015821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given PO
Study NCT00015821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03183102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: 2 months of dietary flaxseed supplementation
Study NCT02448667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FAXE Kondi
Description: Sucrose and glucose containing softdrink
Study NCT02448667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Faxe Kondi Free
Description: Diet softdrink with artificial sweeteners aspartame and acesulfame potassium. Both sweeteners are approved for use as food additives in the European Union and by the FDA. Aspartame metabolism is well understood and normal doses does not affect plasma concentrations of lipids, amino acids, glucose levels, key regulatory hormones or skeletal muscle metabolism. Acesulfame Potassium is not metabolized in humans and is excreted as the parent compound in urine. Since the two artificial sweeteners does not affect skeletal muscle metabolism or blood glucose levels, and both compounds have a well documented safety profiles, FAXE Kondi Free is considered to be an ideal placebo soft drink in this study.
Study NCT02627508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone
Description: orally administered Pregnenolone capsules
Study NCT02627508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally administered placebo capsules
Study NCT00644462 — intervention group
Intervention type: DEVICE
Intervention: PulmoTrack® 2010 with WIM-PC™ Technologies
Description: wheeze detection during dynamic bronchial situations in infants
Study NCT01802437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increase in therapy (4 extra therapy sessions) or fluoxetine therapy. Adolescents who receive pharmacotherapy will be prescribed fluoxetine for 12 weeks. The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and every other week thereafter. If no treatment response was observed by the sixth week, the dosage could be increased to 40 mg per day.
Study NCT01802437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased Dose of Interpersonal Psychotherapy
Description: If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increased dose of interpersonal psychotherapy (4 extra therapy sessions) or fluoxetine.
Study NCT01802437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continue to Receive Initial Dose of Interpersonal Psychotherapy
Description: If Hamilton Rating Scale for Depression scores meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be assigned to continue initial dose of interpersonal psychotherapy.
Study NCT02597907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: aprepitant 80 mg is given to all patients before surgery
Study NCT02597907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: aprepitant 80 mg is given to all patients before surgery
Study NCT02597907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron
Description: palonosetron 0.075 mg is given to patients in the aprepitant plus palonosetron group after induction of general anesthesia
Study NCT02597907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramosetron
Description: ramosetron 0.3 mg is given to patients in the aprepitant plus ramosetron group after induction of general anesthesia
Study NCT03701295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT03701295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pinometostat
Description: Given IV
Study NCT01303120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Preoperative Bupivacaine 0.5%, perineurally as single shot
Study NCT01303120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined nerve blocks
Description: Preoperative Bupivacaine 0.5%, perineurally as single shot
Study NCT01303120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled analgesia
Description: Patient controlled analgesia with morphine
Study NCT02842944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: open loop weaning group (Beacon)
Description: mechanical ventilation following advice from the Beacon Caresystem
Study NCT02842944 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Standardized routine care
Study NCT03940508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Connections Intervention
Description: The MCI is a one to two session intervention that addresses barriers to mental health treatment and helps adolescents build skills to get the most out of their treatment experience. It is designed to be delivered by a trained clinician in conjunction with an evidence-based treatment.
Study NCT03940508 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IPT-A
Description: IPT-A is a time-limited, manualized treatment for depression focused on maladaptive communication patterns and interpersonal interactions.
Study NCT03940508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPT-A
Description: IPT-A is a time-limited, manualized treatment for depression focused on maladaptive communication patterns and interpersonal interactions.
Study NCT00771303 — intervention group
Intervention type: OTHER
Intervention: Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer, lower limb vein ultrasonography and MSCT.
Study NCT03279055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHUTi
Description: Sleep Healthy Using the Internet (SHUTi) is a publicly available insomnia intervention program. It focuses on 5 treatment components that form the core of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention.
Study NCT01295567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Description: prior to CABG surgery 3 day treatment with dipyridamole 200mg SR twice daily
Study NCT01295567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: prior to CABG surgery 3 day treatment with placebo capsules twice daily
Study NCT00596596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: 0,5 mg once daily
Study NCT00596596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: 1 mg once daily
Study NCT00596596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 mg prucalopride
Description: 2 mg once daily
Study NCT00596596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg prucalopride
Description: 4 mg once daily
Study NCT00596596 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo once daily
Study NCT03509116 — intervention group
Intervention type: OTHER
Intervention: Observations, documents
Description: Consultation observations, documentary analysis
Study NCT03509116 — intervention group
Intervention type: OTHER
Intervention: Interviews, key stakeholders, documents
Description: Qualitative interviews, key stakeholders, documentary analysis
Study NCT04384822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Group
Description: Mind-body exercise intervention
Study NCT04384822 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-I Group
Description: First-line clinically recommended non-pharmacological treatment of insomnia
Study NCT02221102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: non-steroidal anti-inflammatory drugs
Study NCT02221102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: edoxaban
Description: orally active direct factor Xa inhibitor
Study NCT02221102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study NCT02221102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT00219440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actos plus standard diet
Description: Actos plus standard diet
Study NCT00219440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actos plus structured diet
Description: Actos plus structured diet
Study NCT00219440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metformin plus standard diet
Description: Metformin plus standard diet
Study NCT02294188 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spatial Repellent product with active ingredient (SHIELD)
Description: Spatial Repellent Product
Study NCT02294188 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active ingredient
Description: Transfluthrin (Active ingredient)
Study NCT02294188 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spatial Repellent product without active ingredient (SHIELD)
Description: Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
Study NCT02648984 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The intervention is performing an exercise test
Description: Patients and controls will undergo a bicycle stress echocardiography and a cardiopulmonary exercise test
Study NCT03098940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chewing Gum
Description: During the study healthy subjects will receive single doses of the various strengths of dronabinol
Study NCT03098940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chewing Gum
Description: During the study healthy subjects will receive single doses of the various strengths of dronabinol
Study NCT01800201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Pill Bottle, Incentives, Social Influence
Description: The intervention group (1) will use GlowCaps, a remote monitoring and reminder pill bottle; (2) assigned an engagement advisor from the study team; (3) asked to provide study team with names and contact information of up to 3 family members or friends as support partners for med adherence. The study team will contact these people in order listed until 1 agrees to this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on med adherence; and (5) will determine preferences for Way to Health platform communication methods.The group receiving the program intervention will also have their claims data analyzed for the 12 months post-enrollment.
Study NCT04144803 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral near-infrared spectroscopy
Description: Nonin H500 one-channel near-infrared spectroscopy monitor on forehead of the patient from before induction of anesthesia to arrival to hospital
Study NCT00118261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Beginning in course 3, patients also receive bevacizumab IV over 30 minutes. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Study NCT00118261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Courses 1-3: oral erlotinib once daily on days 1-14. Patients who do not develop grade 2 toxicity after the first 3 courses (6 weeks) will have their erlotinib dose escalated. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Study NCT00118261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Starting with course 2: fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Study NCT00118261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Starting with course 2: Leucovorin calcium IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Study NCT00118261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Starting with course 2: oxaliplatin IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Study NCT00030420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.
Study NCT00030420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: On day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days
Study NCT04414280 — intervention group
Intervention type: DEVICE
Intervention: Medtronic MiniMed 670G
Description: The Medtronic Minimed 670G system is a form of hybrid closed-loop insulin delivery. The Medtronic MiniMed 670G system automatically adjusts basal insulin every five minutes based on CGM readings to reach a glucose target of 120 mg/dL, the SmartGuard Auto Mode. Patients still need to enter their carbohydrate intake and administer meal-time and correction boluses. Before Auto Mode is introduced, the Medtronic MiniMed 670G system has to be worn in Manual Mode. In contrast to Auto Mode, Manual Mode features an insulin stop up to 30 minutes before or when reaching preset low limits (suspend before/on low) and an automatic insulin restart when blood sugar levels recover. During Manual Mode the pump 'becomes familiar with' the daily insulin need of the patient. This information will be used when in Auto Mode.
Study NCT04414280 — intervention group
Intervention type: DEVICE
Intervention: Medtronic MiniMed 780G
Description: The Medtronic Minimed 780G system differs in several aspects from the MiniMed 670G system. In Auto Mode, the user can choose from two target levels for even more stricter glucose control (100 mg/dL and 120 mg/dL) and correction boluses are now automated without the need of user interaction. When administering meal boluses, no capillary blood glucose value is required. The safety feature to exit from Auto Mode to Manual Mode was too strict in the Minimed 670G. In the Minimed 780G this is more flexible to overcome this frequently reported patient frustration.